Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies
Tóm tắt
Existential distress is a significant source of suffering for patients facing life-threatening illness. Psychedelic-Assisted Therapies (PAT) are novel treatments that have shown promise in treating existential distress, but openness to providing PAT may be limited by stigma surrounding psychedelics and the paucity of education regarding their medical use. How PAT might be integrated into existing treatments for existential distress within palliative care remains underexplored. The present study aimed to elucidate the attitudes of palliative care clinicians regarding treatments for existential distress, including PAT. We recruited palliative care physicians, advanced practice nurses, and spiritual and psychological care providers from multiple US sites using purposive and snowball sampling methods. Attitudes toward PAT were unknown prior to study involvement. Semi-structured interviews targeted at current approaches to existential distress and attitudes toward PAT were analyzed for thematic content. Nineteen respondents (seven physicians, four advanced practice nurses, four chaplains, three social workers, and one psychologist) were interviewed. Identified themes were 1) Existential distress is a common experience that is frequently insufficiently treated within the current treatment framework; 2) Palliative care providers ultimately see existential distress as a psychosocial-spiritual problem that evades medicalized approaches; 3) Palliative care providers believe PAT hold promise for treating existential distress but that a stronger evidence base is needed; 4) Because PAT do not currently fit existing models of existential distress treatment, barriers remain. PAT is seen as a potentially powerful tool to treat refractory existential distress. Larger clinical trials and educational outreach are needed to clarify treatment targets and address safety concerns. Further work to adapt PAT to palliative care settings should emphasize collaboration with spiritual care as well as mental health providers and seek to address unresolved concerns about equitable access.
Tài liệu tham khảo
Boston P, Bruce A, Schreiber R. Existential suffering in the palliative care setting: an integrated literature review. J Pain Symptom Manag. 2011;41(3):604–18.
Roze des Ordons AL, Sinuff T, Stelfox HT, Kondejewski J, Sinclair S. Spiritual distress within inpatient settings - a scoping review of patient and family experiences. J Pain Symptom Manag. 2018;56(1):122–45.
Robinson S, Kissane DW, Brooker J, Burney S. A review of the construct of demoralization: history, definitions, and future directions for palliative care. Am J Hosp Palliat Med. 2014;33(1):93–101.
Vehling S, Kissane DW. Existential distress in cancer: alleviating suffering from fundamental loss and change. Psychooncology. 2018;27(11):2525–30.
Monforte-Royo C, Villavicencio-Chávez C, Tomás-Sábado J, Balaguer A. The wish to hasten death: a review of clinical studies. Psychooncology. 2011;20(8):795–804.
Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M. Understanding the will to live in patients nearing death. Psychosomatics. 2005;46(1):7–10.
Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018;4:Cd011006.
LeMay K, Wilson KG. Treatment of existential distress in life threatening illness: a review of manualized interventions. Clin Psychol Rev. 2008;28(3):472–93.
Grossman CH, Brooker J, Michael N, Kissane D. Death anxiety interventions in patients with advanced cancer: a systematic review. Palliat Med. 2018;32(1):172–84.
Breitbart W, Pessin H, Rosenfeld B, Applebaum AJ, Lichtenthal WG, Li Y, et al. Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: a randomized controlled trial in patients with advanced cancer. Cancer. 2018;124(15):3231–9.
Zheng R, Guo Q, Chen Z, Zeng Y. Dignity therapy, psycho-spiritual well-being and quality of life in the terminally ill: systematic review and meta-analysis. BMJ Support Palliat Care. 2021. https://doi.org/10.1136/bmjspcare-2021-003180.
Rodin G, Lo C, Rydall A, Shnall J, Malfitano C, Chiu A, et al. Managing cancer and living meaningfully (CALM): a randomized controlled trial of a psychological intervention for patients with advanced cancer. J Clin Oncol. 2018;36(23):2422–32.
Bauereiss N, Obermaier S, Ozunal SE, Baumeister H. Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: systematic review and meta-analysis of randomized controlled trials. Psychooncology. 2018;27(11):2531–45.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol (Oxford, England). 2016;30(12):1165–80.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol (Oxford, England). 2016;30(12):1181–97.
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–8.
Iglewicz A, Morrison K, Nelesen RA, Zhan T, Iglewicz B, Fairman N, et al. Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. Psychosomatics. 2015;56(4):329–37.
Falk E, Schlieper D, van Caster P, Lutterbeck MJ, Schwartz J, Cordes J, et al. A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study. BMC Palliat Care. 2020;19(1):1.
Fan W, Yang H, Sun Y, Zhang J, Li G, Zheng Y, et al. Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. Oncotarget. 2017;8(2):2356–60.
Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E, et al. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020;10(1):20442.
Pollan M. How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. New York: Penguin Press; 2018.
Pollan M. My adventures with the trip doctors: the researchers and renegades bringing psychedelic drugs into the mental health mainstream. New York: The New York Times Magazine; 2018.
Byock I. Taking psychedelics seriously. J Palliat Med. 2018;21(4):417–21.
Rosenbaum D, Boyle AB, Rosenblum AM, Ziai S, Chasen MR, Med MP. Psychedelics for psychological and existential distress in palliative and cancer care. Curr Oncol (Toronto, Ont). 2019;26(4):225–6.
Janik P, Kosticova M, Pecenak JP, Turcek M. Categorization of psychoactive substances into “hard drugs” and “soft drugs” a critical review of terminology used in current scientific literature. Am J Drug Alcohol Abuse. 2017;43(6):636–46.
Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369(9566):1047–53.
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology. 2018;142:143–66.
Beaussant Y, Sanders J, Sager Z, Tulsky JA, Braun IM, Blinderman CD, et al. Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: expert clinicians’ and Investigators’ perspectives. J Palliat Med. 2020;23(10):1323–34.
Mayer CE, LeBaron VT, Acquaviva KD. Exploring the use of psilocybin therapy for existential distress: a qualitative study of palliative care provider perceptions. J Psychoactive Drugs. 2021; epub ahead of print.
Mok E, Lau KP, Lam WM, Chan LN, Ng JS, Chan KS. Healthcare professionals’ perceptions of existential distress in patients with advanced cancer. J Adv Nurs. 2010;66(7):1510–22.
Keall R, Clayton JM, Butow P. How do Australian palliative care nurses address existential and spiritual concerns? Facilitators, barriers and strategies. J Clin Nurs. 2014;23(21–22):3197–205.
Fay Z, C OB. How specialist palliative care nurses identify patients with existential distress and manage their needs. Int J Palliat Nurs. 2019;25(5):233–43.
Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. London: SAGE; 2006.
Thornberg RC, Charmaz K. Grounded theory and theoretical coding. In: Flick U, editor. The SAGE handbook of qualitative data analysis. London: SAGE Publications Ltd.; 2014.
Ferrell B, Chung V, Koczywas M, Borneman T, Irish TL, Ruel NH, et al. Spirituality in cancer patients on phase 1 clinical trials. Psychooncology. 2020;29(6):1077–83.
Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18(1):245.
Rosenfeld B, Cham H, Pessin H, Breitbart W. Why is meaning-centered group psychotherapy (MCGP) effective? Enhanced sense of meaning as the mechanism of change for advanced cancer patients. Psychooncology. 2018;27(2):654–60.
Barrett FS, Griffiths RR. Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci. 2018;36:393–430.
Griffiths RR, Johnson MW, Richards WA, Richards BD, Jesse R, MacLean KA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol (Oxford, England). 2018;32(1):49–69.
Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Ponte KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol (Oxford, England). 2020;34(2):155–66.
Sloshower J, Guss J, Krause R, Wallace RM, Williams MT, Reed S, et al. Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. J Contextual Behav Sci. 2020;15:12–9.
Heuschkel K, Kuypers KPC. Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. Front Psychiatry. 2020;11:224.
Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit. 2008;14(8):Sr15–22.
Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Psychological and cognitive effects of long-term peyote use among native Americans. Biol Psychiatry. 2005;58(8):624–31.
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2020;78(5):481–9.
Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235(2):399–408.
Pisano VD, Putnam NP, Kramer HM, Franciotti KJ, Halpern JH, Holden SC. The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol (Oxford, England). 2017;31(5):606–13.
Garcia-Romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol (Oxford, England). 2019;33(9):1088–101.
Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting reductions in Cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: an online survey. Front Psychiatry. 2019;10:955.
Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55–60.
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol (Oxford, England). 2015;29(3):289–99.
Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27:100538.
Swift TC, Belser AB, Agin-Liebes G, Devenot N, Terrana S, Friedman HL, et al. Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol. 2017;57(5):488–519.
Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol (Oxford, England). 2016;30(12):1268–78.
Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, et al. Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front Pharmacol. 2018;9:256.
Barnett BS, Siu WO, Pope HG Jr. A survey of American psychiatrists’ attitudes toward classic hallucinogens. J Nerv Ment Dis. 2018;206(6):476–80.
Davis AK, Agin-Liebes G, Espana M, Pilecki B, Luoma J. Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J Psychoactive Drugs. 2021:1–10. https://doi.org/10.1080/02791072.2021.1971343.